New combo therapy shows promise for rare blood cancer
NCT ID NCT03927105
First seen May 08, 2026 · Last updated May 08, 2026
Summary
This study tested a combination of two drugs, nivolumab and cabiralizumab, in 4 adults with a rare blood cancer called peripheral T-cell lymphoma that had returned or stopped responding to treatment. The goal was to see if the combination could shrink tumors or stop them from growing. The trial is complete, and results focus on how many patients responded within four months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERIPHERAL T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109, United States
-
Unviersity of Wisconsin
Madison, Wisconsin, 53705, United States
Conditions
Explore the condition pages connected to this study.